Perioperative Treatment of Parkinsonian Patients With Parenteral Amantadine

Status

Terminated

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00600093

Enrollment

Registered

2008-01-24

Start date

2008-01-31

Completion date

2011-07-31

Last updated

2011-07-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson Disease, Perioperative Care

Keywords

Amantadine

Brief summary

The purpose of this study is to determine whether administrating of Amantadine (a dopamine agonist) to patients suffering from Parkinson disease during the perioperative period is safe, and to asses potential benefits of this treatment.

Interventions

DRUGAmantadine

IV Amantadine 200mg \*1/d at the beginning of surgery and 24 hours following surgery

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Patient with a diagnosis of Parkinson Disease refered for surgery at our institution.

Exclusion criteria

* Cardiac and neurosurgical procedures * Inability to sign informed Consent * allergy to Amantadine * Congestive heart failure * Arrythmia (including bradycardia below 55 bpm) * renal failure (creatinin above 1.5) * If a patient will develop agitation or delirium lasting longer then 8 hours he will not receive the second dose of amantadine.

Design outcomes

Primary

Measure	Time frame
Mortality, Surgical site infection, Pneumonia, Myocardial Infarction, Cerebral Vascular Accident (CVA).	28 days

Secondary

Measure	Time frame
UPDRS score	2,28 days
Pain (vas score), Analgetic drugs requirement	2 days

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026